At the heart of the controversy is a question many patients and families are asking: Should a drug that might save lives also be allowed to risk them?

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient r...